U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18158338 | https://www.ncbi.nlm.nih.gov/pubmed/28271418 | https://www.ncbi.nlm.nih.gov/pubmed/16380540 | https://www.ncbi.nlm.nih.gov/pubmed/18677709

Angiotensin III (Ang III) is a bioactive heptapeptide that is formed from the degradation of the Angiotensin II peptide by aminopeptidase A. In peripheral Angiotensin systems, Angiotensin II is the main effector peptide in the systemic circulation, although exogenous Angiotensin III can be as potent as Angiotensin II in, for example, stimulating aldosterone secretion or inhibiting renin release. In the rat brain, Angiotensin III was found to be equipotent with Angiotensin II as a pressor agent or dipsogen and was bound as avidly to the nervous system as Angiotensin II. Angiotensin receptor subtype AT1 has the greater affinity towards Angiotensin II and is also responsive to Angiotensin III, while the AT2 receptor subtype appears to be more sensitive to Angiotensin III but less responsive to Angiotensin II. Angiotensin III enhances blood pressure, vasopressin release and thirst when it is centrally administrated. Angiotensin III infusion increases blood pressure in healthy volunteers and hypertensive patients as well as augments aldosterone release. Although Angiotensin III does not change renal function in humans, it induces natriuresis in AT, receptor-blocked rats likely by binding to AT2 receptors. In addition, in cultured renal cells, this peptide stimulates the expression of many growth factors, proinflammatory mediators, and extracellular matrix proteins.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
5.57 nM [IC50]
1.74 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
The biochemistry of the renin-angiotensin system and its role in hypertension.
1976 May 31
[Renin-angiotensin system blockers].
1982
The renin angiotensin system--its physiology and role in disease states.
1983 Nov
The brain renin-angiotensin system.
1984
[Diagnostic tests for endocrine hypertension].
1984 Jan
Control of intestinal absorption by the renin-angiotensin system.
1985 Jul
Renin and reproduction.
1988 Apr
The mas oncogene as a neural peptide receptor: expression, regulation and mechanism of action.
1990
Human angiotensin receptor subtypes.
1994 Jan
Brain angiotensin receptor subtypes in the control of physiological and behavioral responses.
1994 Spring
A case of deoxycorticosterone-producing adrenal adenoma.
1995 Oct
The neuronal role of angiotensin II in thirst, sodium appetite, cognition and memory.
1996 Nov
[Renal effects of AT1 angiotensin receptor antagonists (AT1ra)].
1997 Dec 20
Important role for angiotensin III and IV in the brain renin-angiotensin system.
1997 Sep 30
[Active metabolites derived from angiotensin II].
1998
Bioactive angiotensin peptides.
1998 May
[Angiotensin I, angiotensin II, angiotensin III].
1999 Dec
Role of the renin-angiotensin system in vascular diseases: expanding the field.
2001 Dec 1
Cellular targets for angiotensin II fragments: pharmacological and molecular evidence.
2002 Dec
Organisation and functional role of the brain angiotensin system.
2002 Sep
New bioactive angiotensins formation pathways and functional involvements.
2004
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.
2004 Feb
Role of angiotensin III in hypertension.
2005 Apr
[Angiotensin I, angiotensin II, angiotensin III].
2005 Aug
Gene regulation and physiological function of placental leucine aminopeptidase/oxytocinase during pregnancy.
2005 Aug 1
Dietary fat and hypertension: a novel approach through the proteolytic regulatory enzymes of the renin-angiotensin-system.
2006 Jul
Brain aminopeptidases and hypertension.
2006 Sep
Patents

Patents

Sample Use Guides

Ang III (3.5, 7, and 14 nmol/kg per minute) was infused cumulatively into the renal interstitialspace of the left (experimental) kidney each rat after a 1-hour control infusion
Route of Administration: Other
Human prostate cancer cell (DU145 and LNCaP) were used for activity evaluation. LNCaP and DU145 cells were seeded onto 24-well plates at a density of 2–5x10^4 cells/well. Cells were treated with Ang-III at various concentrations as indicated in the figures for 5 days. Simultaneously, the cells were pretreated with olmesartan for 30 min, and cultured in phenol red-freeRPMI plus 0.1% BSA in the presence of Ang-III for 5 days. After incubation in 5% CO2 at 37C, cells were harvested with trypsin and cell numbers were determined with a cell counter on day 5.
Name Type Language
ANGIOTENSIN III ACETATE
Common Name English
2-8-ANGIOTENSIN II, 5-L-ISOLEUCINE-, ACETATE
Common Name English
ANGIOTENSIN III, 4-L-ISOLEUCINE-, MONOACETATE (SALT)
Common Name English
Code System Code Type Description
PUBCHEM
72941629
Created by admin on Sat Dec 16 09:28:38 GMT 2023 , Edited by admin on Sat Dec 16 09:28:38 GMT 2023
PRIMARY
CAS
1354552-78-5
Created by admin on Sat Dec 16 09:28:38 GMT 2023 , Edited by admin on Sat Dec 16 09:28:38 GMT 2023
NON-SPECIFIC STOICHIOMETRY
FDA UNII
2AY78S427U
Created by admin on Sat Dec 16 09:28:38 GMT 2023 , Edited by admin on Sat Dec 16 09:28:38 GMT 2023
PRIMARY
CAS
100900-06-9
Created by admin on Sat Dec 16 09:28:38 GMT 2023 , Edited by admin on Sat Dec 16 09:28:38 GMT 2023
PRIMARY